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     The distinction between normal aging and Alzheimer’s disease (AD) is a first and relevant step to 
combat this disease efficiently. Because of the clinical interest in predicting patient evolution and 
prognosis, the identification of biomarkers and the unraveling of genetic factors underlying AD are of 
crucial importance. 
     Several lines of evidence implicate an imbalance of the redox-active biometals, as iron in AD. Metal-
catalyzed hydroxyl radicals are potent mediators of cellular injury and are central to the oxidative injury 
hypothesis of AD pathogenesis [1,2].  
     In this study, we seek to further investigate this hypothesis through the identification of serum 
biomarkers/endophenotypes related to Fe metabolism and candidate genes involved in Fe homeostasis.  
     This integrative approach is planned to deal with heterogeneity in these complex disorder and further 
elucidate the contribution of Fe metabolism disruption to the etiopathogenesis of AD.  
Subjects and sample collection 
       A total of 116 AD patients and 98 healthy volunteers were recruited at Hospital de Santa Maria, Hospital 
Fernando Fonseca and Hospital Magalhães Lemos. Blood samples were collected by venipuncture in serum gel 
and EDTA tubes. The study was submitted and approved by the local ethics committee and each donor or legal 
representative signed an informed consent before blood collection. 
 
Genetic Analysis 
       A total of 74 SNPs were evaluated by highthroughput genotyping in APOE (apolipoprotein E) and 9 Fe 
metabolism-related genes: CYBRD1 (cytochrome b reductase 1), HAMP (hepcidin), HFE (hemochromatosis 
gene), IREB1/2 (iron responsive element binding protein 1/2), SLC11A2 (divalent metal transporter 1), SLC40A1 
(ferroportin), TF (transferrin) and TFR2 (transferrin receptor 2). SNPassoc® package for R 2.8.1® (1999-2006 R 
Development Core Team) was used for logistic regression analysis of the genotyping data for association with 
AD (adjusted for sex and gender). P-values <0.05 were considered statistically significant. 
 
Biochemical measurements 
       Serum iron (Fe), transferrin (Tf), ferritin (Ft) concentration and transferrin saturation (Tf Sat.) were measured 
by standard methods. PASW Statistics 18.0® (SPSS Inc.) software was used for MANCOVA and logistic 
regression analysis of all biochemical data. 
 
Gene expression evaluation 
       Total RNA was extracted from PBMCs (peripheral blood mononuclear cells) of 59 control and 53 AD 
individuals and the expression of HPRT1, TFRC, TFR2, SLC40A1, HAMP and SLC11A2 genes was analysed by 
real-time PCR. 
PASW Statistics 18.0® (SPSS Inc.) software was used to perform the analysis of variance, adjusted for age and 
gender (ANCOVA), of gene expression data. 
 
 The overall results obtained in this work provide additional evidence that strengthen the hypothesis of an altered Fe homeostasis in Alzheimer’s disease.  
Fe metabolism biomarkers measured in serum (Fe, Tf and Ft concentration) were found significantly decreased in AD patients when compared to controls. Also, associations with AD were 
found for three SNPs in TF, one SNP in TFR2 and for the first time in IREB1 and SLC40A1 genes. In addition, evidence for the down-regulation of TFR1, TFR2 and SLC40A1 gene expression in 
AD patients was found. 
 Importantly, this study is in agreement with previous reports of an association of APOE ε4 with AD, thus reproducing well-accepted results and reinforcing the validity of our work.  
 
 
 
 We hypothesize that the lower serum Fe concentration observed in AD patients can be due to impaired Fe excretion from cells, since ferroportin (Fpn) codified by SLC40A1 is the only known 
Fe exporter in mammalian cells. Also, the TFR2 polymorphism found to be associated with AD is located at the putative promoter region of the TfR2_beta isoform which is involved in SLC40A1 
transcriptional regulation. On the other hand, IREB1 codifies a cytosolic protein which binds to iron-responsive elements (IREs) found in RNA from several iron metabolism-related proteins as 
ferritin, TfR, Fpn itself and importantly amyloid precursor protein (APP). The intracellular accumulation of Fe, particularly in the brain where Fpn is also expressed, would lead to a rise in 
oxidative damage, contributing to the AD physiopathology. 
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Table 1. Results of significant SNP allelic association in iron-related genes and APOE with AD. 
Mb: Megabases; OR: odds ratio; 95% CI: 95% confidence interval; NS: not significant; a: minor/major allele; *: rs1439816 in SLC40A1 gene is located in intron 1 in a boundary region to exon 2 (at 24 bp) .  
Significant P-values (<0.05) and significant Bonferroni corrected P-values (P-valuecorr; <0.05) are highlighted in bold.   
Table 2. Biochemical parameters measured in serum from AD cases and controls and respective 
multivariate analysis of variance. 
Significant values (<0.05) are highlighted in bold. 
 Six SNPs in iron-related genes have been shown associated with AD.  
The associated alleles in TFR2 and TF SNPs confer protection to AD while the ones in SLC40A1 and IREB1 are 
associated to AD risk. 
 Only the TFR2 association survives Bonferroni correction at the gene level. 
 APOE ε4 association with AD risk was confirmed in our study. 
 Both serum iron, ferritin and transferrin levels were found to be significantly decreased in AD patients.  
 No significant differences have been found with the Transferrin Saturation levels.   
 The expression of TFR1, TFR2 and SLC40A1 genes in PBMCs from AD patients is significantly 
decreased when compared to controls. 
 The expression of HAMP and 
SLC11A2 genes were not significantly 
different when comparing AD patients to 
controls. 
The quantification was performed by normalizing the sample to a pool of individuals and using HPRT1 as a housekeeping gene. Dots represent the mild outliers. The number of 
individuals analyzed is indicated in brackets. 
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Gene Chromosome SNP reference Position (Mb) Allelesa Gene region 
Associated Allele numbers 
(frequency) Associated 
Allele 
P-value OR(95% CI) P-valuecorr 
AD                
(2n = 232) 
CTRL               
(2n = 178) 
SLC40A1 2q32 rs1439816 190152875 C/G Intron 1* 44 (0.190) 19 (0.107) C 2.10E-02 1.96 (3.49-1.10) NS 
TF 3q22.1 rs4428180 134949064 G/A Intron 1 32 (0.138) 37 (0.210) G 5.37E-02 0.60 (1.01-0.36) NS 
TF 3q22.1 rs1358024 134966878 T/C Intron 11 24 (0.104) 30 (0.174) T 4.15E-02 0.55 (0.98-0.31) NS 
TF 3q22.1 rs8177277 134967520 C/T Intron 11 7 (0.030) 15 (0.085) C 1.47E-02 0.33 (0.84-0.13) NS 
TFR2 7q22 rs7385804 100073906 A/C Intron 3 90 (0.395) 83 (0.539) C 5.50E-03 0.56 (0.37-0.84) 1.65E-02 
IREB1 9p21.1 rs10970973 32414900 C/G Intron 10 76 (0.349) 42 (0.244) C 2.58E-02 1.66 (2.59-1.06) NS 
APOE 19q13.2 rs429358 50103781 C/T Exon 4 58 (0.271) 18 (0.123) C 7.00E-04 2.64 (4.71-1.48) 7.00E-04 
                        
Parameters 
AD Cases   Controls 
Normal range 
Significance 
(F) 
Overall 
MANCOVA 
(F) n mean ± SD    n mean ± SD 
[Iron] (µg/dL) 116 76.63 ± 26.36 84 86.67 ± 25.18 37.0 – 158.0 0.003 (4.19) 
0.003          
(6.27) 
[Transferrin] (mg/dL) 114 250.96 ± 43.23 84 267.86 ± 44.28 200.0 – 400.0 0.016 (3.16) 
Transferrin Saturation (%) 113 23.43 ± 8.17 83 25.70 ± 7.91 25.0 – 50.0 0.066 (2.25) 
[Ferritin] (ng/µL) 101 126.91 ± 70.00   81 138.40 ± 83.91 6.0 – 397.0 0.033 (2.69) 
